References
- Sivaraman S, Venugopal P, Ranganathan R, Deshpande C G, Huang X, Jajeh A, et al. Effect of interferon-α on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 2000; 6: 81–87
- Davis T A, Maloney D G, Grillo-Lopez A J, White C A, Williams M E, Weiner G J, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000; 6: 2644–2652
- Sacchi S, Federico M, Vitolo U. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958
- Manns M, McHuntchinson J G, Gordon S C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a random trial. Lancet 2001; 358: 958–965
- Cheson B, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardized response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
- Schwartz A, Repollet E F, Vogt R, Gratama J W. Standardizing flow cytometry: construction of a standardized fluorescence calibration plot using matching spectral calibrators. Cytometry 1996; 26: 22–31
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
- Rohatiner A Z, Gregory W M, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
- Lindsay K L, Trepo C, Heintges T, Shiffman M L, Gordon S C, Hoefs J C, et al. A randomized, double-blind trial comparing Pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis. Hepatology 2001; 34: 395–403
- Hainsworth J D, Litchy S, Burris H A, III, Scullin D C, Jr, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
- Ghielmini M, Schmitz S F, Cogliatti S, Bertoni F, Waltzer U, Fey M F, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705–711
- Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Grimaldi M, Greco F A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095
- Pan D C, Zelenetz A D, Kostmayer S S, Giles F, Agus D B. Variable expression and lack of cytokine modulation of the CD20 antigen in human B-cell lymphoma cell lines. Proc Am Soc Hematol 1999; 94: 4329
- D'Arcy C A, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rhem 2001; 44: 1717–1718
- Herishanu Y. Rituximab-induced serum sickness. Amer J Hematol 2002; 70: 329
- Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 2003; 36: 519–523